These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34716336)

  • 1. Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect.
    Ruiz García Y; Sohn WY; Seib KL; Taha MK; Vázquez JA; de Lemos APS; Vadivelu K; Pizza M; Rappuoli R; Bekkat-Berkani R
    NPJ Vaccines; 2021 Oct; 6(1):130. PubMed ID: 34716336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 4. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
    Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
    BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California.
    Bruxvoort KJ; Lewnard JA; Chen LH; Tseng HF; Chang J; Veltman J; Marrazzo J; Qian L
    Clin Infect Dis; 2023 Feb; 76(3):e1341-e1349. PubMed ID: 35642527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.